Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the prior-year quarter, driven by $11 million in net sales of TONMYA, its recently approved fibromyalgia treatment. The company reported 12,592 total prescriptions for TONMYA during the quarter, a 100% sequential increase, with new patient prescriptions rising 36% and refills surging 207%. This strong uptake underscores the demand for a new treatment option in a therapeutic area that has seen limited innovation for over a decade.
TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the first new treatment for fibromyalgia in more than 15 years, representing a significant milestone for patients and the medical community. The drug's commercial performance is supported by broad market access, with coverage currently representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to about 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027, potentially increasing patient access and driving further sales growth.
The company's robust financial results are accompanied by continued progress in its clinical pipeline. Tonix has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder, a condition that affects millions worldwide. Additionally, the company is preparing to initiate an adaptive Phase 2 field study of TNX-4800, a monoclonal antibody for Lyme disease prevention, in the first quarter of 2027, pending final FDA review and agreement on the protocol. These programs highlight Tonix's commitment to addressing areas of high unmet medical need in both central nervous system (CNS) and immunology.
The company ended the quarter with approximately $176.2 million in cash and cash equivalents. According to management, these resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides stability as Tonix continues to commercialize TONMYA and advance its pipeline.
The significance of this announcement extends beyond Tonix's financial performance. TONMYA's rapid adoption reflects a positive shift for fibromyalgia patients, who have had limited FDA-approved options. The drug's sales growth also demonstrates the commercial viability of repurposing existing molecules for new indications, which could encourage further innovation in CNS disorders. Moreover, the company's pipeline progress, particularly in major depressive disorder and Lyme disease prevention, addresses substantial public health concerns. Major depressive disorder is one of the leading causes of disability globally, while Lyme disease affects hundreds of thousands of people annually, with no vaccine currently available for humans.
Tonix's integrated approach, combining commercial products and a diverse pipeline, positions it to potentially become a significant player in the biotech industry. The company's CNS portfolio also includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare genetic disorder. In immunology, TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection, is under development. These efforts underscore the company's focus on conditions with significant unmet needs.
As Tonix continues to execute its commercial and clinical strategies, the impact on patients, healthcare providers, and investors will be closely watched. The company's ability to sustain TONMYA's momentum and advance its pipeline will be key to its long-term success. For more information on Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP.
